Patent: 9,226,973
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,226,973
Title: | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
Abstract: | The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. |
Inventor(s): | Govindan; Serengulam V. (Summit, NJ), Goldenberg; David M. (Mendham, NJ) |
Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
Application Number: | 14/204,698 |
Patent Claims: | see list of patent claims |
Details for Patent 9,226,973
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2032-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |